Augmented renal clearance: implications for antibacterial dosing in the critically ill.
about
Advances in antibiotic therapy in the critically illOptimizing antimicrobial therapy in critically ill patientsVancomycin dosing in neutropenic patientsEstimation of creatinine clearance using plasma creatinine or cystatin C: a secondary analysis of two pharmacokinetic studies in surgical ICU patientsOseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patientsAntibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.Broad-spectrum β-lactams in obese non-critically ill patients.Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds.The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort studyVancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery.A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance.Therapeutic drug monitoring of antimicrobials.Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunctionProtein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patientsPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children.Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.Screening of patients with augmented renal clearance in ICU: taking into account the CKD-EPI equation, the age, and the cause of admission.Therapeutic Drug Monitoring of Continuous Infusion Doripenem in a Pediatric Patient on Continuous Renal Replacement Therapy.The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.Pharmacokinetic evaluation of fluconazole in critically ill patients.Year in review 2010: Critical Care--Infection.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.Approaches for dosage individualisation in critically ill patients.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Using quality improvement principles to improve the care of patients with severe sepsis and septic shock.Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injuryImplications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Medicating patients during extracorporeal membrane oxygenation: the evidence is building.The pharmacokinetics of propofol in ICU patients undergoing long-term sedation.Vancomycin Pharmacokinetic Parameters in Patients with Hemorrhagic Stroke.Optimal teicoplanin dosage regimens for methicillin-resistant Staphylococcus aureus infections in endocarditis patients and renal failure patients.Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
P2860
Q26749328-1F084431-A676-42E9-97D1-366CB524E413Q26999905-65CD73DC-1BCB-4309-A7F9-8DBD1A4DA19CQ28544891-420F9E8B-FB8C-4792-987E-48603747D7BBQ30316598-54C8BAF2-38C5-40EE-BAB3-A77AFD588B54Q30407250-94317D16-84FC-4886-9E4E-C9ECB755CC9FQ33751132-9072FD30-66D1-4FD1-B132-FFC8F483CF81Q33752635-EDF172FC-F6A4-4DBA-8A2A-DA9FAD2C7EFDQ33821972-6281B8FA-98B3-4ADC-9C6C-57E85C2A4ED8Q33824276-73D457ED-429C-4A02-BA4F-C9D1EF404415Q33839225-03D30A62-4ED5-4016-BE9C-52FE9101AECEQ34739945-67CD0D5F-A86A-4CEC-9D77-8F707E051193Q34996307-8319FD75-472F-4368-B812-1B04EFC7D2CBQ35004943-41B5BF69-8EA8-4661-A97B-5642413636D2Q35124710-853D1604-8DE4-4F31-9C9C-059FC58B0B63Q35364423-E2E03E02-E77C-455B-B7F1-01DA07B5D9C4Q35558309-BC06CA1D-F782-4DE2-AB99-F0261A76FC69Q35640430-C9CF76B6-552E-4F34-B957-56E330B93298Q35676081-0CD81CA6-FFEA-4BFA-9B33-68BD6F4B0252Q36072500-C99953F3-8277-4E1A-ABB1-E67ECB99B74FQ36083619-CFE7335F-74C6-4A02-963E-059AA967560DQ36158484-C6D05F61-F0B4-47E9-8F18-1F2E951BD2BEQ36364174-59590824-C15D-4EF9-8266-D4839AECD4BAQ36376844-4B8B7ABD-B05A-48E5-982C-B4C682B2A583Q37686607-4611F86D-F0EC-4D40-8FCC-4C82376F014FQ37818164-09EC03F3-4649-4906-805F-E01209875674Q37924819-E77AF127-ABF4-44E5-919F-447DFF8AFC52Q37966018-ABDB9FF5-93A7-445C-AF87-FCEDF9B000B1Q38004063-19E4EED3-783A-471E-9132-5BE52E30F2C9Q38107537-6D33F982-DED3-4175-A8E2-4D663BBBFABEQ38125209-6F817A35-8FA1-4F88-9B53-F67C18CF3F2EQ38138835-AB342728-3BE3-43FC-876E-480E176B01F4Q38139926-28255945-D71D-45E5-AF98-8E19584412CAQ38365787-DF2C34A7-69D5-44A0-931B-993D99FADF2CQ38644824-971CBD51-5BD0-4616-91AD-1EDE80E68F41Q38837353-D81DE969-2A43-4708-8173-2A464707515FQ39188586-1F6E1987-FE12-4C9D-9157-729C0E4757ECQ39457828-4173719A-7B59-4066-9494-6A9EAC9AF3FDQ39948315-85A8ED68-D0BE-4D2B-9E1A-459E7C84DF08Q40183072-F6D70011-6E67-447E-A8F5-26FEB22E88E5Q40233756-5941E172-E21B-476F-A80C-B344BDBC7CDB
P2860
Augmented renal clearance: implications for antibacterial dosing in the critically ill.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Augmented renal clearance: implications for antibacterial dosing in the critically ill.
@en
Augmented renal clearance: implications for antibacterial dosing in the critically ill.
@nl
type
label
Augmented renal clearance: implications for antibacterial dosing in the critically ill.
@en
Augmented renal clearance: implications for antibacterial dosing in the critically ill.
@nl
prefLabel
Augmented renal clearance: implications for antibacterial dosing in the critically ill.
@en
Augmented renal clearance: implications for antibacterial dosing in the critically ill.
@nl
P2860
P50
P1476
Augmented renal clearance: implications for antibacterial dosing in the critically ill.
@en
P2093
Jeffrey Lipman
Robert J Boots
P2860
P356
10.2165/11318140-000000000-00000
P577
2010-01-01T00:00:00Z